Skip directly to content


1. MacFarlane LA, Todd DJ. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis. Int J Rheum Dis. 2014;17(4):359-368.
2. Clark JD, Flanagan ME. Discovery and development of Janus Kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023-5038.
3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
4. Tofacitinib for the treatment of rheumatoid arthritis. Advisory committee briefing document. May 9, 2012 Accessed November 20, 2014.
5. Lundquist LM, Cole SW. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop. 2014;5(4):504-511.
6. Zerbini CA, Lomonte AB. Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2012;8(4):319-331.
7. Waldburger JM, Firestein GS. Garden of therapeutic delights: new targets in rheumatic diseases. Arthritis Res Ther. 2009;11(1):206. doi:10.1186/ar2556.
8. Cohen MD, Keystone EC. JAK inhibitors for rheumatoid arthritis. Curr Treat Options in Rheum. 2015;1:305-319.
9. Mócsai A, Kovacs L. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med. 2014;12:43.
10. Barclay N, Tarallo M. Patient preference for oral versus injectable and intravenous methods of treatment for rheumatoid arthritis. PMS 78. Value Health. 2013;16:A568.
11. XELJANZ Documento local de producto CDSv 16.0 Fecha Efectiva: 26 de enero 2018
12. XELJANZ XR Documento Local de Producto CDSv 8.0


Este material es de uso exclusivo para el cuerpo médico. ©Pfizer S.A.S. Todos los derechos reservados – Prohibida su reproducción total o parcial sin autorización del titular.

 Volver a menú